What is Claimed:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is H or F;

R^2 is H or F;

R^3 is OH or F;

R^4 is CN, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_4 cycloalkyl, azido, halogen, or C_1-C_2 haloalkyl;

R^6 is OH;

R^5 is selected from the group of H and:

 ,  ,  ,



and



wherein:

n’ is selected from 1, 2, 3, and 4;

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, -O-benzyl, -CH_2-C_3-C_6 cycloalkyl, -O-CH_2-C_3-C_6 cycloalkyl, and CF_3;

R^9 is selected from phenyl, 1-naphthyl, 2-naphthyl,



and



R^{10} is selected from H and CH_3;

R^{11} is selected from H or C_1-C_6 alkyl;

R^{12} is selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and –CH_2-C_3-C_6 cycloalkyl.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is H.

3. A compound according to Claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^2 is H.

4. A compound according to any of Claims 1- 3, or a pharmaceutically acceptable salt thereof, of Formula (II):



(II)

wherein:

R^3 is OH or F;

R^4 is CN, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_4 cycloalkyl, azido, halogen, or C_1-C_2 haloalkyl;

R^5 is selected from the group of H and:


,

,

,


,
and

;

wherein:

n' is selected from 1, 2, 3, and 4;

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, -O-benzyl, -CH_2-C_3-C_6 cycloalkyl, -O-CH_2-C_3-C_6 cycloalkyl, and CF_3;

R^9 is phenyl;

R^{10} is selected from H and CH_3;

R^{11} is selected from H or C_1-C_6 alkyl;

R^{12} is selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and $–CH_2$-C_3-C_6 cycloalkyl.

5. A compound according to any of Claims 1- 4, or a pharmaceutically acceptable salt thereof, wherein R^4 is CN, methyl, ethyl, ethenyl, ethynyl, azido, F, Cl, $-CH_2Cl$, $-CH_2F$, $-CHF_2$, or $–CF_3$.

6. A compound according to any of Claims 1- 5, or a pharmaceutically acceptable salt thereof, wherein R^3 is F.

7. A compound according to any of Claims 1- 5, or a pharmaceutically acceptable salt thereof, wherein R^3 is OH.

8. A compound according to Claim 4, or a pharmaceutically acceptable salt thereof, wherein R^4 is CN.

9. A compound according to Claim 4, or a pharmaceutically acceptable salt thereof, wherein both R^1 and R^2 are H and R^4 is methyl, ethyl, vinyl, or ethynyl; or

a compound according to Claim 4, or a pharmaceutically acceptable salt thereof, wherein R^4 is methyl, ethyl, vinyl, or ethynyl.

10. A compound according to Claim 6 or 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is halomethyl.

11. A compound according to any of Claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^5 is H.

12. A compound according to any of Claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the group of:



wherein:

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, and -CH_2-C_3-C_6 cycloalkyl; and

R^{12} is selected from C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and –CH_2-C_3-C_6 cycloalkyl.

13. A compound according to any of Claims 1-12, or a pharmaceutically acceptable salt thereof, wherein either:

(A) R^8 is selected from C_1-C_8 alkyl; or

(B) R^8 is selected from C_1-C_6 alkyl; or

(C) R^8 is selected from C_1-C_5 alkyl; or

(D) R^8 is selected from C_1-C_4 alkyl; or

(E) R^{12} is selected from C_1-C_8 alkyl; or

(F) R^{12} is selected from C_1-C_4 alkyl.

14. A compound according to any of Claims 1-13, or a pharmaceutically acceptable salt thereof, further comprising the proviso that when R^3 is F, R^4 is not methyl.

15. A compound according to any of Claims 1- 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the group of H and:

(a)  , (b)  , and (c)  .

16. A compound according to any of Claims 1-15, or a pharmaceutically acceptable salt thereof, selected from the group of:

(A)

 ,  ,  ,  ,

 , and  . ; or

(B)


,

,

,

,

,

,
and

.

or

(C)


,

,

,

,
and

.

; or

(D)


,

,

,

,

, and

.

; or

(E)


,

,

,

,

,

and

.

; or

(F)


,

,

, and

.

17. A pharmaceutical formulation comprising a pharmaceutically effective amount of a compound of any of Claims 1-16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

18. A compound of any of Claims 1-16, or a pharmaceutically acceptable salt thereof, for use in the treatment of a *Pneumovirinae* virus infection or a respiratory syncytial virus infection in a human.

19. A compound selected from Formula

(i) (A), Formula (B), Formula (C), Formula (D), and Formula (E):



(A) ;



(B) ;



(C) ;



(D) ; and



(F) ;

wherein X^1 is an oxygen protecting group which is

a silyl ether protecting group selected from Trimethylsilyl (TMS), Triethylsilyl (TES), Dimethylisopropylsilyl (IPDMS), Diethylisopropylsilyl (DEIPS), Dimethylthexylsilyl (TDS), t-Butyldimethylsilyl (TBS or TBDMS), *t*-Butyldiphenylsilyl (TBDPS), Tribenzylsilyl, Tri-*p*-xylylxilyl, Triisopropylsilyl (TIPS), Diphenylmethylsilyl (DPMS), Di-*t*-butylmethylsilyl (DTBMS), Triphenylsilyl (TPS),Methyldiphenylsilyl (MDPS), *t*-butylmethoxyphenylsilyl, Tris(trimethylsilyl)silyl (sisyl), (2-Hydroxystyryl)dimethylsilyl (HSDMS), (2-Hydroxystyryl)diisopropylsilyl (HSDIS). *t*-Butylmethoxyphenylsilyl (TBMPS), and *t*-Butoxydiphenylsilyl (DPTBOS) protecting groups; or

a benzyl-type protecting group selected from benzyl, halogenated benzyl, *p*-methoxybenzyl, benzyloxymethyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 2,6-dimethoxybenzyl, *p*-CF_3-benzyl, *p*-methylbenzyl, *p*-methoxylbenzyl, 3,5-dimethylbenzyl, *p*-tert-butylbenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-halobenzyl, including *p*-Br-benzyl, 2,6-dichlorobenzyl, *p*-cyanobenzyl, *p*-phenylbenzyl, 2,6-difluorobenzyl, *p*-acylaminobenzyl (PAB), *p*-azidobenzyl (Azb), 4-azido-3-chlorobenzyl, 2-trifluoromethylbenzyl, *p*-(methylsulfinyl)benzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, 2-quinolinylmethyl, diphenylmethyl (DPM), *p,p'*-dinitrobenzhydryl, triphenylmethyl, alpha-naphthyldiphenylmethyl, *p*-methoxyphenyldiphenylmethyl, di(*p*-methoxyphenyl)phenylmethyl, tri(*p*-methoxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, and 2-naphthylmethyl;

and X^2 is an amine protecting group which is

selected from *p*-methoxybenzyl carbonyl (Moz or MeOZ), acetyl (Ac), benzoyl (Bz), *p*-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), *p*-methoxyphenyl (PMP), tosyl (Ts or Tos), trifluoroacetamide, and trityl; or

a carbamate protecting group selected from 9-fluorenylmethyloxycarbonyl (FMOC), 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 17-tetrabenzo[*a*,*c*,*g*,*i*]fluorenylmethyl (Tbfmoc), 2-chloro-3-indenylmethyl (Climoc), benz[*f*]inden-3-ylmethyl (Bimoc), 2,7-di-*t*-butyl[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanyl)]methyl (DBD-Tmoc), [2-(1,3-dithianyl)methyl (Dmoc), 1,1-dioxobenzo[*b*]thiophene-2-ylmethyl (Bsmoc), 1,1-dimethyl-2-cyanoethyl, 2-phosphonioethyl (Peoc), 2-methylthioethyl, 2-(*p*-toluenesulfonyl)ethyl, 2,2,2,-trichloroethyl (Troc), 2-(trimethylsilyl)ethyl (Teoc), 2-phenylethyl (hZ), 1-(1-adamantyl)-1-methylethyl (Adpoc), 1,1-dimethyl-2-bromoethyl, 1,1-dimethyl-2-chloroethyl, 1,1-dimethyl-2,2-dibromoethyl (DB-*t*-BOC), 1,1-dimethyl-2,2,2-trichloroethyl (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl (Bpoc), 1-(3,5-di-*t*-butylphenyl)-1-methylethyl (*t*-Bumeoc), 2-(2'pyridyl)ethyl, 2-(4'pyridyl)ethyl, 2,2-bis(4'-nitrophenyl)ethyl (Bnpeoc), *N*-(2-pivaloylamino)-1,1,dimethylethyl, 2-[(2-nitrophenyl)dithio]-1-phenylethyl (NpSSPeoc), 2-(*N*,*N*-dicyclohexylcarboxamido)ethyl, *t*-butyl (Boc or BOC), 1-adamantyl (1-Adoc), 2-adamantyl (2-Adoc), vinyl (Voc), allyl (Aloc or alloc), 1-isopropylallyl (Ipaoc), cinnamyl (Coc), 4-nitrocinnamyl (Noc), 3-(3'-pyridyl)prop-2-enyl (Paloc), 8-quinolyl, and *N*-hydroxypiperidinyl, carbamates, as well as alkyldithio carbamates, including methyldithio, ethyldithio, isopropyldithio, t-butyldithio, phenyldithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl (Msz), 9-anthrylmethyl, 4-methylthiophenyl (Mtpc), 1-methyl-1-(triphenylphosphonio)ethyl (2-triphenylphosphonioisopropyl) (Ppoc), 2-dansylethyl (Dnseoc), 2-(4-nitrophenyl)ethyl (Npeoc), 4-phenylacetoxybenzyl (PhAcOZ), 4-azidobenzyl (ACBZ), 4-azidomethoxybenzyl, *m*-chloro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, carbobenzyloxy (Cbz), 4-benzisoxazolylmethyl (Bic), 2-(trifluoromethyl)-6-chromonylmethyl (Tcroc), phenyl, and diphenylmethyl carbamates. Additional carbamates include butynyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1,1-dimethylpropynyl, and 1-methyl-1-cyclopropylmethyl carbamates;

or an amide protecting group for amines selected from *N*-formyl, *N*-acetyl, *N*-chloroacetyl, *N*-trichloroacetyl, *N*-trifluoroacetyl (TFA), *N*-phenylacetyl, *N*-3-phenylpropionyl, *N*-4-pentenoyl, *N*-picolinoyl, *N*-3-pyridylcarboxamido, *N*-benzoylphenylalanyl, *N*-benzoyl, and *N*-*p*-phenylbenzoyl amides; or

(ii) a compound of selected from:



,


,


,

and


.

20. Use of a compound of any of Claims 1- 16, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment in a human of a *Pneumovirinae* virus infection or a respiratory syncytial virus infection.